Abstract
Seven paediatric patients with central diabetes insipidus were studied in an open dose ranging study in hospital followed by a six month study on an outpatient basis to assess the efficacy and safety of peroral administration of DDAVP (desmopressin) tablets. In the dose ranging study a dose dependent antidiuretic response was observed. The response to 12.5-50 mcg was, however, less effective in correcting baseline polyuria than were doses of 100 mcg and above. Patients were discharged from hospital on a preliminary dosage regimen ranging from 100 to 400 mcg three times daily. After an initial adjustment in dosage in three patients at one week follow up, all patients were stabilised on treatment with tablets and reported an adequate water turnover at six months. As with the intranasal route of administration dosage requirements varied from patient to patient, and a dose range rather than standard doses were required. A significant correlation, however, was found for the relation between previous intranasal and present oral daily dosage. No adverse reactions were reported. No clinically significant changes were noted in blood chemistry and urinalysis. All patients expressed a preference for the oral over existing intranasal treatment. Treatment with tablets offers a beneficial alternative to the intranasal route, particularly in patients with chronic rhinitis or impaired vision.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Adibi S. A. Intestinal transport of dipeptides in man: relative importance of hydrolysis and intact absorption. J Clin Invest. 1971 Nov;50(11):2266–2275. doi: 10.1172/JCI106724. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Andersson K. E., Arner B. Effects of DDAVP, a synthetic analogue of vasopressin, in patients with cranial diabetes insipidus. Acta Med Scand. 1972 Jul-Aug;192(1-2):21–27. doi: 10.1111/j.0954-6820.1972.tb04772.x. [DOI] [PubMed] [Google Scholar]
- Andersson K. E., Arner B., Fürst E., Hedner P. Antidiuretic responses to hypertonic saline infusion, water deprivation, and a synthetic analogue of vasopressin in patients with hereditary, hypothalamic diabetes insipidus. Acta Med Scand. 1974 Jan-Feb;195(1-2):17–23. doi: 10.1111/j.0954-6820.1974.tb08089.x. [DOI] [PubMed] [Google Scholar]
- Arafah B. M., Manni A., Brodkey J. S., Kaufman B., Velasco M., Pearson O. H. Cure of hypogonadism after removal of prolactin-secreting adenomas in men. J Clin Endocrinol Metab. 1981 Jan;52(1):91–94. doi: 10.1210/jcem-52-1-91. [DOI] [PubMed] [Google Scholar]
- Grossman A., Fabbri A., Goldberg P. L., Besser G. M. Two new modes of desmopressin (DDAVP) administration. Br Med J. 1980 May 17;280(6225):1215–1215. doi: 10.1136/bmj.280.6225.1215. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Hammer M., Vilhardt H. Peroral treatment of diabetes insipidus with a polypeptide hormone analog, desmopressin. J Pharmacol Exp Ther. 1985 Sep;234(3):754–760. [PubMed] [Google Scholar]
- Letter: Serum immunoglobulins in idiopathic minimal-change nephrotic syndrome. N Engl J Med. 1976 Jan 1;294(1):50–51. doi: 10.1056/NEJM197601012940117. [DOI] [PubMed] [Google Scholar]
- Saffran M., Franco-Saenz R., Kong A., Papahadjopoulos D., Szoka F. A model for the study of the oral administration of peptide hormones. Can J Biochem. 1979 Jun;57(6):548–553. doi: 10.1139/o79-069. [DOI] [PubMed] [Google Scholar]
- Seif S. M., Zenser T. V., Ciarochi F. F., Davis B. B., Robinson A. G. DDAVP (1-desamino-8-D-arginine-vasopressin) treatment of central diabetes insipidus--mechanism of prolonged antidiuresis. J Clin Endocrinol Metab. 1978 Mar;46(3):381–388. doi: 10.1210/jcem-46-3-381. [DOI] [PubMed] [Google Scholar]
- Vilhardt H., Bie P. Antidiuretic response in conscious dogs following peroral administration of arginine vasopressin and its analogues. Eur J Pharmacol. 1983 Sep 30;93(3-4):201–204. doi: 10.1016/0014-2999(83)90138-3. [DOI] [PubMed] [Google Scholar]